Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotevtamab plus FOLFOX as Neoadjuvant Therapy for Colorectal Cancer Liver Metastases
NCT06225843Phase 2Recruiting
- Sponsor
- Alethia Biotherapeutics
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotevtamab in metastatic colorectal cancer (mCRC), sponsored by Alethia Biotherapeutics. Primary endpoints: Rubbia-Brandt score at surgery and Treatment-Emergent Adverse Events. Started Feb 2024; status: recruiting.
02
Drugs
sotevtamab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06225843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225843.